Table of Contents

Definition

Biofabrication is the automated production of complex, functional, living biological products from raw materials that include living cells, cell aggregates, extracellular matrices, biomaterials, and bioactive molecules¹. The field is formally positioned as comprising two complementary strategies: bioprinting, in which cells and materials are patterned by additive manufacturing, and bioassembly, in which self-organizing cellular units are guided into larger structures¹.

The biological basis of biofabrication is the layer-by-layer construction of three-dimensional, tissue-like architectures from cell-laden hydrogel precursor solutions, designated bioinks, in which living cells are suspended within hydrated polymer networks². Structurally, each deposited layer is stabilized by a crosslinking process, which may be ionic, thermal, or photoinitiated, and the resulting matrix must simultaneously preserve shape fidelity and permit the diffusion of oxygen and nutrients to embedded cells³. At the cellular level, construct maturation is governed by cell adhesion to the surrounding matrix, cell-mediated matrix remodeling and deposition, paracrine signaling between co-fabricated cell types, and mechanotransductive responses to the viscoelastic environment, while the shear stresses imposed during deposition constitute the principal mechanical constraint on cell survival^{3 4}.

Purpose

The primary value proposition of biofabrication is the reproducible, automated, and potentially patient-specific manufacture of living, human-relevant tissue constructs, a capability that manual scaffold seeding and conventional fabrication cannot provide at equivalent fidelity^{1 4}. Biofabrication improves upon legacy in vitro models because planar, two-dimensional cultures fail to reproduce the architecture, cell density, and matrix context of native tissue, whereas printed or assembled three-dimensional constructs approximate native tissue geometry and composition^{5 6}.

Its human relevance is twofold. First, constructs are fabricated with human cells and can therefore recapitulate human physiology more faithfully than animal models, which supports their use in research, drug discovery, and toxicology⁵. Second, biofabrication addresses the persistent shortage of transplantable tissues; bioprinting has already been used for the generation and transplantation of multilayered skin, bone, vascular grafts, tracheal splints, heart tissue, and cartilaginous structures⁵.

Methodology

Biofabrication workflows generally proceed from medical imaging or computer-aided design of the target geometry to the formulation of cell-compatible materials and, finally, to automated deposition and maturation of the construct^{5 7}.

Key techniques comprise three established deposition modalities. Inkjet bioprinting ejects low-viscosity bioinks, on the order of 3.5 to 12 mPa·s, as discrete droplets at high rates of up to 10,000 droplets per second. Microextrusion bioprinting dispenses high-viscosity bioinks, ranging from approximately 30 mPa·s to more than 6 × 10⁷ mPa·s, by pneumatic, piston, or screw drive, which permits physiologically relevant cell densities. Laser-assisted bioprinting transfers cells from a donor film by laser-induced forward transfer and accommodates bioink viscosities of roughly 1 to 300 mPa·s⁵. Light-based vat photopolymerization, in which photoreactive resins are crosslinked by patterned illumination, constitutes a further fabrication route⁴.

Substrates are predominantly hydrogels of natural origin, including alginate, gelatin, gelatin methacrylate, collagen, fibrin, and hyaluronic acid, together with synthetic systems such as poly(ethylene glycol)-based gels, selected for their cytocompatibility and tunable crosslinking^{2 3}. Crosslinking and gelation are achieved by ionic complexation, as in calcium-mediated alginate gelation, by thermal gelation, or by photopolymerization initiated with suitable photoinitiators, and the rheological profile, gelation kinetics, and shear-thinning behavior of the bioink must be engineered to balance printability against cell survival³.

Growth factors are delivered within the construct or through perfusion; vascularized printed tissues have been perfused with osteogenic growth-factor cocktails for extended periods to induce in situ differentiation of human mesenchymal stem cells⁸. Instrumentation includes sterile multi-cartridge bioprinters, integrated systems that deposit cell-laden hydrogels together with biodegradable polymer microchannels to permit nutrient diffusion in large constructs, and perfusion chambers and bioreactors that support maturation under controlled conditions^{7 8}.

Performance

Empirical performance is modality dependent. Inkjet systems achieve droplet volumes from below 1 pL to above 300 pL and feature widths of approximately 50 µm at high deposition rates⁵. Microextrusion produces filaments ranging from approximately 5 µm to millimeter scale and tolerates the highest material viscosities and cell densities of the established modalities⁵. Laser-assisted bioprinting achieves microscale resolution and, because it is nozzle-free and therefore imposes minimal shear on cells, preserves the highest post-printing viability, above 95 percent, whereas extrusion-based processes, which subject cells to sustained shear stress, typically yield cell viabilities of approximately 40 to 80 percent⁵. Volumetric bioprinting has demonstrated the fastest fabrication times reported to date, forming entire cell-laden, anatomically shaped constructs within seconds to tens of seconds⁹.

At the construct scale, integrated printing systems have produced human-scale bone, cartilage, and skeletal muscle constructs with structural integrity, enabled by embedded perfusion microchannels⁷. Multimaterial bioprinting has yielded vascularized human tissues exceeding one centimeter in thickness, containing an engineered extracellular matrix, embedded vasculature, and multiple cell types, that remained viable under active perfusion with growth factors for more than six weeks and supported in situ osteogenic differentiation of human mesenchymal stem cells⁸.

Reproducibility is being formalized through standards. ASTM International has published a standard guide for bioinks used in bioprinting that specifies formulation, viscoelastic and chemical properties, crosslinking mechanism, sterility, and cellular component considerations, principally for extrusion-based fabrication of tissue-engineered medical products¹⁰. Nevertheless, current technical boundaries remain substantial: the consistent product quality required by medical device regulations is not yet guaranteed for cell-bearing printed grafts⁶, and the field continues to be constrained by vascularization of thick constructs, the recapitulation of multicellular organ-level complexity, and long-term functional maturation⁴.

Applications

Primary research applications are physiologically relevant three-dimensional tissue and organ models for disease modeling, drug discovery, and toxicology screening, for which bioprinted constructs offer human-cell-based alternatives to animal experimentation^{5 4}. Primary industrial applications lie in regenerative medicine and transplantation, where bioprinting has been used to generate and transplant multilayered skin, bone, vascular grafts, tracheal splints, heart tissue, and cartilaginous structures, and in high-throughput pharmaceutical tissue models⁵.

Deployment has begun in the clinic in selected contexts. A customized, bioresorbable tracheal splint fabricated by three-dimensional printing from computed tomography data was implanted in an infant with life-threatening tracheobronchomalacia, with resolution of symptoms following implantation¹¹. Additive manufacturing has also been adopted for medical devices more broadly, as exemplified by approved three-dimensionally printed titanium hip implant components¹.

Standardized contexts of use are emerging rather than established: the ASTM guide for bioinks defines terminology and pre-, during-, and post-printing considerations for extrusion-based processes, but comprehensive standards covering the full spectrum of biofabrication technologies do not yet exist¹⁰. Overall readiness is therefore highest for research and pharmaceutical in vitro models, intermediate for implantable acellular or minimally cellular devices, and earliest for fully cellularized implantable tissues, where clinical evidence remains limited to first-in-human cases^{5 11}.

Variations

• Inkjet Bioprinting — Drop-on-demand ejection of low-viscosity bioinks of approximately 3.5 to 12 mPa·s at rates of up to 10,000 droplets per second, producing droplets below 1 pL and features of approximately 50 µm, at the cost of limited cell concentrations⁵.

• Extrusion Bioprinting — Pneumatic or mechanical dispensing of bioinks with viscosities up to more than 6 × 10⁷ mPa·s, enabling physiologically relevant cell densities and larger constructs, with filament dimensions from approximately 5 µm to millimeter scale^{5 7}.

• Laser-Assisted Bioprinting — Nozzle-free transfer of cells from a donor film by laser-induced forward transfer, accommodating viscosities of approximately 1 to 300 mPa·s, achieving microscale resolution, and preserving the highest post-printing cell viability of the established modalities^{5 4}.

• Vat Photopolymerization Bioprinting — Light-initiated crosslinking of photoreactive bioinks by patterned illumination, as in stereolithography and digital light processing, offering microscale resolution and high fabrication throughput⁴.

• Volumetric Bioprinting — Tomographic light projections that crosslink entire cell-laden constructs in a single step, forming anatomically shaped, clinically relevant constructs within seconds to tens of seconds while maintaining high cell viability⁹.

• Melt Electrowriting — Direct writing of an electrified polymer melt jet along a digitally controlled path, producing ordered, micron-scale fibrous scaffolds with high structural precision for tissue engineering¹².

• Scaffold-Free Bioassembly — Guided or autonomous self-organization of cellular units such as tissue spheroids into larger constructs without exogenous matrices, constituting the complementary assembly strategy to bioprinting within the field^{1 4}.